Group members

Alirezaylavasani A, Egner IM, Dahl B, Chopra A, de Matos Kasahara T, Goll GL, Jahnsen J, Grødeland G, Vaage JT, Lund-Johansen F, Holter JC, Halvorsen B, Jørgensen KK, Munthe LA, Kared H (2024)
Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease
Clin Immunol, 271, 110404
DOI 10.1016/j.clim.2024.110404, PubMed 39645159

Ørbo HS, de Matos Kasahara T, Wolf AS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Solum G, Kjønstad IF, Bhandari S, Christensen IE, Kvien TK, Lind A, Kared H, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Mjaaland S, Syversen SW, Jørgensen KK, Grødeland G, Goll GL (2024)
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study
Lancet Reg Health Eur, 48, 101121
DOI 10.1016/j.lanepe.2024.101121, PubMed 39624496

Wolf AS, Bjørlykke KH, Ørbo HS, Bhandari S, Solum G, Kjønstad IF, Jyssum I, Nygaard UC, Kristoffersen AB, Christensen IE, Josefsson SE, Lund KP, Chopra A, Osen JR, Chaban V, Tveter AT, Sexton J, Kvien TK, Jahnsen J, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Kared H, Lund-Johansen F et al. (2024)
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
EBioMedicine, 108, 105317
DOI 10.1016/j.ebiom.2024.105317, PubMed 39260039